2 citations
,
February 2025 in “Journal of the European Academy of Dermatology and Venereology” JAK inhibitors may effectively treat lichen planopilaris and frontal fibrosing alopecia with minimal side effects.
2 citations
,
May 2024 in “Expert Opinion on Drug Safety” Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.
2 citations
,
March 2024 in “Meditsinskiy sovet = Medical Council” JAK inhibitors effectively treat severe atopic dermatitis and alopecia areata.
2 citations
,
April 2023 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology” JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
2 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
1 citations
,
July 2026 in “Dermatology and Therapy” JAK inhibitors are generally safe for alopecia areata and atopic dermatitis, with mostly mild side effects.
1 citations
,
May 2024 in “International Journal of Innovative Science and Research Technology (IJISRT)” JAK inhibitors effectively treat Lichen Planopilaris, but long-term safety is uncertain.
1 citations
,
December 2022 in “The Nishinihon Journal of Dermatology” Baricitinib is an effective treatment for severe alopecia areata.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
August 2026 in “Australasian Journal of Dermatology” JAK inhibitors improved hair regrowth in children with alopecia areata and were generally safe.
July 2026 in “Zenodo (CERN European Organization for Nuclear Research)” JAK inhibitors may help treat alopecia areata by restoring hair growth.
July 2026 in “Zenodo (CERN European Organization for Nuclear Research)” JAK inhibitors may help treat alopecia areata by restoring hair growth.
July 2026 in “Journal of the American Academy of Dermatology” Infections and missed treatments trigger flares in alopecia areata patients on JAK inhibitors.
June 2026 in “Acta Dermato Venereologica” JAK inhibitors can help some people with long-standing alopecia areata regrow hair, but many stop treatment due to limited effectiveness.
June 2026 in “Journal of Cosmetic and Regenerative Medicine” JAK inhibitors effectively treat certain skin diseases but need careful use due to potential safety concerns.
June 2026 in “Saudi Medical Horizons Journal” JAK inhibitors show promise in treating skin conditions like eczema, hair loss, and vitiligo but need more safety research.
May 2026 in “Acta Dermato Venereologica” Early treatment with JAK inhibitors leads to better hair regrowth in acute alopecia areata.
March 2026 in “Lithuanian University of Health Sciences” JAK inhibitors can effectively regrow hair in alopecia areata patients, but ongoing treatment is needed to maintain results.
March 2026 in “Expert Opinion on Pharmacotherapy” JAK inhibitors are effective for severe alopecia areata but need better strategies for long-term use and personalized treatment.
March 2026 in “JMIR Dermatology” Interest in JAK inhibitors for alopecia areata increased significantly after FDA approval, highlighting the need for patient education.
February 2026 in “Frontiers in Medicine” Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.
February 2026 in “Colloids and Surfaces A Physicochemical and Engineering Aspects” JAK inhibitors can enter the skin through hair follicles using a unique pathway.
January 2026 in “Medicina” JAK inhibitors show promise for treating various skin disorders effectively and safely.
January 2026 in “Skin Health and Disease” Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
November 2025 in “Journal of Dermatological Treatment” Dexamethasone oral mini-pulse therapy effectively treats severe alopecia areata when JAK inhibitors can't be used.
November 2025 in “Journal of Cutaneous Medicine and Surgery” JAK inhibitors are effective and safe for treating severe alopecia areata.
September 2025 in “Acta Dermato Venereologica” Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.
September 2025 in “Journal of the American Academy of Dermatology” Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
September 2025 in “DiRROS repository (University of Maribor)” JAK inhibitors can effectively regrow hair in alopecia areata.
August 2025 in “Dermatology and Therapy” JAK inhibitors show promise for treating alopecia areata but have serious side effects.